Welcome

Redwood Pharma AB is a company whose mission is to develop new ophthalmic pharmaceutical therapies where there are large and unmet market needs. It has in-licensed, IntelliGel, a proprietary and patented hydrogel drug delivery platform technology that will reduce dosages, dosing-frequency and, thereby, potential systemic toxicities of active pharmaceutical ingredients. The Company’s lead development product is a new therapy to treat chronic Dry Eye Disease (DED) in post-menopausal women. With an ageing population, DED affects more and more people hindering many in their daily activities such as reading, using a computer and driving an automobile.

Redwood Pharma Presentations

Aktiespararnas Småbolagsdagen Stockholm
Sheraton Hotel Stockholm
11 June 2018, kl. (TBD)
Sign up here: www.aktiespararna.se (live broadcasting)

Latest Events

March 5, 2018 – Video interview during Aktiedagen Stockholm 2018
January 30, 2018 – Video interview during Aktiedagen Lund 2018
June 13, 2017 – Analyst Group presents investment analysis of Redwood Pharma
February 15, 2017 – Redwood Pharma AB – End of Year Report 2016
November 24, 2016 – Redwood Pharma AB – Interim Report Q3 2016
August 30, 2016 – Redwood Pharma AB – Interim Report Jan-June 2016

News